Alberto Risueño
YOU?
Author Swipe
View article: Extended exposure to low doses of azacitidine induces differentiation of leukemic stem cells through activation of myeloperoxidase
Extended exposure to low doses of azacitidine induces differentiation of leukemic stem cells through activation of myeloperoxidase Open
Oral azacitidine (Oral-Aza; CC-486) treatment results in longer median overall survival (OS) (24.7 vs 14.8 months in placebo) in patients with acute myeloid leukemia (AML) in remission after intensive chemotherapy. The dosing schedule of O…
View article: Luspatercept stimulates erythropoiesis, increases iron utilization, and redistributes body iron in transfusion‐dependent thalassemia
Luspatercept stimulates erythropoiesis, increases iron utilization, and redistributes body iron in transfusion‐dependent thalassemia Open
Luspatercept, a ligand‐trapping fusion protein, binds select TGF‐β superfamily ligands implicated in thalassemic erythropoiesis, promoting late‐stage erythroid maturation. Luspatercept reduced transfusion burden in the BELIEVE trial (NCT02…
View article: Molecular Features Associated with Response to Enasidenib Plus Azacitidine in Newly Diagnosed IDH2-Mutated Acute Myeloid Leukemia
Molecular Features Associated with Response to Enasidenib Plus Azacitidine in Newly Diagnosed IDH2-Mutated Acute Myeloid Leukemia Open
IDH2 gene mutations, typically at residues R140 and R172, occur in 8–19% of patients with acute myeloid leukemia (AML). These mutations induce production of 2-hydroxyglutarate (2-HG), an oncometabolite that causes DNA and histone hypermeth…
View article: P459: DISEASE MONITORING OF NPM1-MUTANT (MUT) ACUTE MYELOID LEUKEMIA (AML) USING MEASURABLE RESIDUAL DISEASE (MRD) ASSESSMENTS DURING ORAL AZACITIDINE (ORAL-AZA) TREATMENT (TX): A QUAZAR AML-001 SUBANALYSIS
P459: DISEASE MONITORING OF NPM1-MUTANT (MUT) ACUTE MYELOID LEUKEMIA (AML) USING MEASURABLE RESIDUAL DISEASE (MRD) ASSESSMENTS DURING ORAL AZACITIDINE (ORAL-AZA) TREATMENT (TX): A QUAZAR AML-001 SUBANALYSIS Open
Background:NPM1 is mutated in 20–30% of patients (pts) with AML at diagnosis (Dx), with greater frequency among pts with normal karyotype. As NPM1 mutations are generally stable at relapse and AML-specific, dynamic PCR-based measurement of…
View article: P997: FEDRATINIB IS EFFECTIVE IN RUXOLITINIB-RESISTANT CELLS: CLINICAL AND PRECLINICAL CORRELATIONS
P997: FEDRATINIB IS EFFECTIVE IN RUXOLITINIB-RESISTANT CELLS: CLINICAL AND PRECLINICAL CORRELATIONS Open
Topic: 15. Myeloproliferative neoplasms - Biology & Translational Research Background: Myelofibrosis (MF) is a clonal myeloproliferative neoplasm characterized by a hyperactive JAK-STAT pathway, bone marrow fibrosis, extramedullary hematop…
View article: P411: LONGITUDINAL CHARACTERIZATION OF MOLECULAR VARIANTS AT REMISSION AND RELAPSE: SUBANALYSIS OF THE QUAZAR AML-001 TRIAL
P411: LONGITUDINAL CHARACTERIZATION OF MOLECULAR VARIANTS AT REMISSION AND RELAPSE: SUBANALYSIS OF THE QUAZAR AML-001 TRIAL Open
Background: Acute myeloid leukemia (AML) is characteristically heterogeneous, with outcomes impacted by age, cytogenetics and molecular factors. Despite achieving remission with frontline intensive chemotherapy (IC), most patients (pts) ev…
View article: Long‐term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo‐controlled, phase 3 <scp>QUAZAR AML</scp>‐001 trial
Long‐term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo‐controlled, phase 3 <span>QUAZAR AML</span>‐001 trial Open
Despite recent therapeutic advances, outcomes remain poor for older patients with acute myeloid leukemia (AML). For patients in the USA diagnosed with AML between 2010–2017, the 5-year overall survival (OS) rate was 22% for patients aged 6…
View article: Prognostic impact of <i>NPM1</i> and <i>FLT3</i> mutations in patients with AML in first remission treated with oral azacitidine
Prognostic impact of <i>NPM1</i> and <i>FLT3</i> mutations in patients with AML in first remission treated with oral azacitidine Open
The randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial (ClinicalTrials.gov identifier: NCT01757535) evaluated oral azacitidine (Oral-AZA) in patients with acute myeloid leukemia (AML) in first remission after intensive chemothera…
View article: Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status
Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status Open
Measurable residual disease (MRD) in patients with acute myeloid leukemia (AML) in remission after intensive chemotherapy is predictive of early relapse and poor survival. Postremission maintenance therapy that prolongs MRD negativity or c…
View article: Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier
Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier Open
Treatment options for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) are limited, with no standard of care; prognosis is poor, with 4- to 6-month median survival. Avadomide (CC-122) is a cereblon-modulating agent with immu…
View article: Leveraging Gene Expression Subgroups to Classify DLBCL Patients and Enrich for Clinical Benefit to a Novel Agent
Leveraging Gene Expression Subgroups to Classify DLBCL Patients and Enrich for Clinical Benefit to a Novel Agent Open
Diffuse large B-cell lymphoma is a heterogeneous disease, commonly described by cell-of-origin (COO) molecular subtypes. We sought to identify novel patient subgroups through an unsupervised analysis of a large public dataset of gene expre…
View article: Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study
Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study Open
The authors report a phase 1 study of romidepsin combined with oral 5-azacytidine in patients with relapsed/refractory lymphomas, including complete remissions in 3 patients with angioimmunoblastic T-cell lymphoma.
View article: S143 LUSPATERCEPT INCREASES FETAL HEMOGLOBIN (HBF) LEVELS IN ADULT β‐THALASSEMIA PATIENTS WHO REQUIRE RED BLOOD CELL (RBC) TRANSFUSIONS
S143 LUSPATERCEPT INCREASES FETAL HEMOGLOBIN (HBF) LEVELS IN ADULT β‐THALASSEMIA PATIENTS WHO REQUIRE RED BLOOD CELL (RBC) TRANSFUSIONS Open
Background: The β‐thalassemias are a group of inherited disorders characterized by absent or reduced production of the β‐globin chains of hemoglobin (Hb), leading to ineffective erythropoiesis, chronic anemia, and multiple morbidities, and…
View article: DECO: decompose heterogeneous population cohorts for patient stratification and discovery of sample biomarkers using omic data profiling
DECO: decompose heterogeneous population cohorts for patient stratification and discovery of sample biomarkers using omic data profiling Open
Motivation Patient and sample diversity is one of the main challenges when dealing with clinical cohorts in biomedical genomics studies. During last decade, several methods have been developed to identify biomarkers assigned to specific in…
View article: Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib
Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib Open
Approximately 8% to 19% of patients with acute myeloid leukemia (AML) have isocitrate dehydrogenase-2 (IDH2) mutations, which occur at active site arginine residues R140 and R172. IDH2 mutations produce an oncometabolite, 2-hydroxyglutarat…
View article: ColoLipidGene: signature of lipid metabolism-related genes to predict prognosis in stage-II colon cancer patients
ColoLipidGene: signature of lipid metabolism-related genes to predict prognosis in stage-II colon cancer patients Open
Lipid metabolism plays an essential role in carcinogenesis due to the requirements of tumoral cells to sustain increased structural, energetic and biosynthetic precursor demands for cell proliferation. We investigated the association betwe…